ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2007 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2006--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm (ET) on Thursday, November 2, 2006. The call will include management discussion of financial results and provide an update on ImmunoGen.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be heard through the Investor Relations section on the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 9, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Five anticancer compounds are in clinical testing through ImmunoGen and the Company's Collaborators - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor, Genentech, Millennium Pharmaceuticals, Inc., and sanofi-aventis have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with sanofi-aventis.
CONTACT:
ImmunoGen, Inc.
Carol Hausner, Executive Director
Investor Relations and Corporate Communications
617-995-2500
info@immunogen.com
SOURCE:
ImmunoGen, Inc.
